Kurum Yazarı "Ölmez, Ömer Fatih" Tıp Fakültesi İçin Listeleme
-
Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes
Yıldız, Anıl; Bilici, Ahmet; Açıkgöz, Özgür; Hamdard, Jamshid; Basım, Pelin; Çakır, Tansel; Çakır, Aslı; Ölmez, Ömer Fatih; Gezen, Cem; Yıldız, Özcan (Taylor and Francis Ltd., 2024)The current study was designed to assess the response to treatment, as well as clinical and survival outcomes, across different breast cancer subtypes in patients who underwent neoadjuvant chemotherapy (NAC). From 2014 to ... -
The prognostic role of mismatch repair status and CDX-2 expression with inflammatory markers and pathological risk factors in stage ıı and ııı colon cancer: Multicenter real-life data
Aydın, Sabin Göktaş; Ölmez, Ömer Fatih; Selvi, Oğuzhan; Geredeli, Çağlayan; Özden, Ferhat; Bilici, Ahmet; Açıkgöz, Özgür; Karcı, Ebru; Kutlu, Yasin; Hamdard, Jamshid; Aydın, Ahmet (2024)Objective: Colorectal cancer is common worldwide, and adjuvant treatment’s benefit is still controversial. We designed this study to determine the role of MSI and CDX-2 status determined by immunohistochemistry (IHC) ... -
Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer
Kutlu, Yasin; Çekin, Ruhper; Göktaş Aydın, Sabin; Shbair, Abdallah T. M.; Bilici, Ahmet; Arıcı, Serdar; Öven, Bala Başak; Açıkgöz, Özgür; Özcan, Erkan; Ölmez, Ömer Fatih; Çakır, Aslı; Şeker, Mesut (2024)Loss of human epidermal growth factor receptor 2 (HER2) expression can be seen in almost 25–30 % patients after HER2 receptor directed neoadjuvant treatment. These patients have unclear clinical outcomes in previous studies. ... -
Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study
Bilici, Ahmet; Uysal, Mükremin; Menekşe, Serkan; Akın, Semih; Yıldız, Fatih; Turan, Merve; Sezgin Göksu, Sema; Beypınar, İsmail; Sakalar, Teoman; Değirmenci, Mustafa; Erdem, Dilek; Başaran, Gül; Ölmez, Ömer Fatih; Avcı, Nilüfer; Tural, Deniz; Sakin, Abdullah; Türker, Sema; Demir, Atakan; Temiz, Süleyman; Kaplan, Muhammed Ali; Doğan, Mutlu; Tanrıverdi, Özgür; Bilgetekin, İrem; Yeşil Çınkır, Havva; Açıkgöz, Özgür; Paydaş, Semra; Uslu, Rüçhan; Turhal, Serdar (Taylor & Francis Inc, 2022)Purpose: This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) metastatic breast cancer (MBC) ... -
Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer
Göktaş Aydın, Sabin; Açıkgöz, Özgür; Kutlu, Yasin; Bilici, Ahmet; Hamdard, Jamshid; Ölmez, Ömer Fatih; Yıldız, Özcan (Ankara Society of Hematology and Oncology, 2021)Background: Immunotherapy agents such as atezolizumab and nivolumab are appropriate option for non-small cell lung cancer (NSCLC) accounts in the absence of driver mutation, regardless of PDL-1 expression in second and ... -
Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer
Erol, Vedat Buğra; Göktaş Aydın, Sabin; Bilici, Ahmet; Çakır, Aslı; Açıkgöz, Özgür; Ölmez, Ömer Fatih; Basım, Pelin (Taylor and Francis Ltd., 2023)To evaluate the tumour-infiltrating lymphocyte (TIL) rates in breast tissue before and after neoadjuvant chemotherapy (NAC) and their impact on survival, eighty-four patients with locally advanced breast cancer (LABC) were ... -
The relationship between the change with neoadjuvant chemotherapy in the tumor-infiltrating lymphocyte (TIL) expressions and pathological response in breast cancer patients.
Bilici, Ahmet; Göktaş Aydın, Sabin; Çakır, Aslı; Ölmez, Ömer Fatih; Erol, Vedat Buğra (Lippincott Williams & Wilkins, 2023)... -
Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma
Tural, Deniz; Selçukbiricik, Fatih; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Erman, Mustafa; Coşkun, Hasan Şenol; Artaç, Mehmet; Kılıçkap, Saadettin (Springer, 2022)Background Atezolizumab (ATZ) has demonstrated antitumor activity in previous studies in patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of ATZ was modest. Therefore, finding ... -
The role of 18F-FDG PET/CT in predicting the neoadjuvant treatment response in patients with locally advanced breast cancer
Göktaş Aydın, Sabin; Bilici, Ahmet; Ölmez, Ömer Fatih; Öven, Bala Başak; Açıkgöz, Özgür; Çakır, Tansel; Basım, Pelin; Çakır, Aslı; Kutlu, Yasin; Hamdard, Jamshid (Karger, 2022)Purpose: Patients with locally advanced breast cancer (LABC) should be treated with neoadjuvant chemotherapy (NAC). Pathological complete response (pCR) is related to better disease-free survival (DFS). The best strategy ... -
Survival effect of palliative radiotherapy in patients with metastatic castration-resistant prostate cancer developing oligo-progression under antiandrogen treatment
Göktaş Aydın, Sabin; Kutlu, Yasin; Muğlu, Harun; Açıkgöz, Özgür; Aydın, Ahmet; Bilici, Ahmet; Ölmez, Ömer Fatih; Ünal, Dilek; Karcı, Ebru; Yıldız, Özcan (Istanbul University, 2023)Objective: Androgen pathway inhibitors have a significant impact on the treatment of prostate cancer. The treatment approach is controversial in patients who develop oligo-pro-gression under anti-androgen therapy. This ... -
Survival outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical therapy: A multicenter analysis
Açıkgöz, Özgür; Bilici, Ahmet; Tataroğlu Özyükseler, Deniz; Göktaş Aydin, Sabin; Selçukbiricik, Fatih; Rzazade, Rashad; Ölmez, Ömer Fatih; Başak Çağlar, Hale (Turkiye Klinikleri, 2023)Background/aim: Oligometastatic disease for nonsmall cell lung cancer (NSCLC) patients is generally thought to represent a better prognosis with a quieter biology, limited number of disease sites and long-term disease ...